Jaume Pons

Jaume Pons

Company: ALX Oncology

Job title: President & Chief Executive Officer


Evorpacept: a Phase 2 CD47 Blocker Uniquely Designed for Use in Combination Therapies to Safely Maximize Anti-Cancer Activity 11:30 am

• ALX Oncology’s lead product candidate, evorpacept, is a next-generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain • Evorpacept has demonstrated promising clinical responses and tolerability across a range of hematologic and solid malignancies in combination with targeted antibodies, pembrolizumab, and chemotherapy • ALX is currently…Read more

day: Day One Track B AM

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.